A Phase 1 interventional study of Drug Cocktail and Mirikizumab in Psoriasis, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-29.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 30th largest by enrollment, is one of 6 that started in 2018, is one of 9 in phase 1, and was the 26th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 181 across the 36 interventional studies. Of the 35 that completed or were terminated, 28 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Psoriasis by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab.
The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Participants received a single dose of the following drug cocktail on Day 1: 1 mg midazolam, 10 mg warfarin, 10 mg vitamin K, 30 mg dextromethorphan, 20 mg omeprazole, 100 mg Caffeine administered orally
Drug: Drug Cocktail
Period 2: Participants received 250 mg mirikizumab subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks (Days 1 to Day 113) Period 2: Participants received the second dose of the drug cocktail: 1 mg midazolam, 10 mg warfarin, 10 mg vitamin K, 30 mg dextromethorphan, 20 mg omeprazole, 100 mg caffeine administered orally on Day 116.
Drug: Drug Cocktail · Drug: Mirikizumab
Drug pages: Caffeine · Warfarin · Dextromethorphan · Midazolam · Omeprazole · Vitamin K 1
Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
Administered SC
Also known as: LY3074828
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Midazolam
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Midazolam
Time frame: Period 1: Day 1: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 2: 24 hours; Period 2: Day 116: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 117: 24 hours; post-dose
PK: Cmax of Warfarin
PK: Cmax of Warfarin
Time frame: Period 1: Day 1: predose,1,2, 4,6, 8 and 10 hours, Day 2: 24 hours, Day 3: 48 hours, Day 4: 72 hours, Day 5: 96 hours; Period 2: Day 116: predose,1,2,4,6,8 and 10 hours, Day 117: 24 hours, Day 118: 48 hours, Day 119: 72 hours, Day 120: 96 hours;post-dose
PK: Cmax of Dextromethorphan
PK: Cmax of Dextromethorphan
Time frame: Period 1: Day 1: predose, 1, 2, 4, 6, 8 and 10 hours, Day 2: 24 hours, Day 3: 48 hours, Day 4: 72 hours; Period 2: Day 116: predose, 1, 2,4, 6, 8 and 10 hours, Day 117: 24 hours, Day 118: 48 hours, Day 119: 72 hours;post-dose
PK: Cmax of Omeprazole
PK: Cmax of Omeprazole
Time frame: Period 1: Day 1: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 2: 24 hours, Day 3: 48 hours; Period 2: Day 116: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 117: 24 hours, Day 118: 48 hours;post-dose
PK: Cmax of Caffeine
PK: Cmax of Caffeine
Time frame: Period 1: Day 1: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 2: 24 hours, Day 3: 48 hours; Period 2: Day 116: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 117: 24 hours, Day 118: 48 hours;post-dose
PK: Area Under the Concentration Curve (AUC) Time Zero to Infinity (AUC [0-∞]) of Midazolam
PK: Area Under the Concentration Curve (AUC) Time Zero to Infinity (AUC \[0-∞\]) of Midazolam
Time frame: Period 1: Day 1: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 2: 24 hours; Period 2: Day 116: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 117: 24 hours;post-dose
PK: AUC Time Zero to Infinity (AUC[0-∞]) of Warfarin
PK: AUC Time Zero to Infinity (AUC\[0-∞\]) of Warfarin
Time frame: Period 1: Day 1: predose,1,2,4,6,8 and 10 hours, Day 2: 24 hours, Day 3: 48 hours, Day 4: 72 hours, Day 5: 96 hours; Period 2: Day 116: predose, 1, 2, 4, 6, 8 and 10 hours, Day 117: 24 hours, Day 118: 48 hours,Day 119: 72 hours,Day 120: 96 hours;post-dose
PK: AUC Time Zero to Infinity (AUC[0-∞]) of Dextromethorphan
PK: AUC Time Zero to Infinity (AUC\[0-∞\]) of Dextromethorphan
Time frame: Period 1: Day 1: predose,1,2,4,6,8 and 10 hours, Day 2: 24 hours, Day 3: 48 hours, Day 4: 72 hours; Period 2: Day 116: predose, 1, 2,4, 6, 8 and 10 hours, Day 117: 24 hours, Day 118: 48 hours, Day 119: 72 hours;post-dose
PK: AUC Time Zero to Infinity (AUC[0-∞]) of Omeprazole
PK: AUC Time Zero to Infinity (AUC\[0-∞\]) of Omeprazole
Time frame: Period 1: Day 1: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 2: 24 hours, Day 3: 48 hours; Period 2: Day 116: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 117: 24 hours, Day 118: 48 hours;post-dose
PK: AUC Time Zero to Infinity (AUC[0-∞]) of Caffeine
PK: AUC Time Zero to Infinity (AUC\[0-∞\]) of Caffeine
Time frame: Period 1: Day 1: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 2: 24 hours, Day 3: 48 hours; Period 2: Day 116: predose, 0.5, 1, 2, 3, 4, 6, 8 and 12 hours, Day 117: 24 hours, Day 118: 48 hours;post-dose
| Milestone | Drug Cocktail | Mirikizumab + Drug Cocktail |
|---|---|---|
| Started | 29 | 0 |
| Received at least one dose of study drug | 29 | 0 |
| Completed | 29 | 0 |
| Not completed | 0 | 0 |
| Milestone | Drug Cocktail | Mirikizumab + Drug Cocktail |
|---|---|---|
| Started | 0 | 29 |
| Completed | 0 | 26 |
| Not completed | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 |
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Midazolam
| Nanograms per millilitre (ng/mL) | Period 1: 1 mg Midazolam | Period 2: 1 mg Midazolam |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Midazolam | 4.07 ± 29 | 4.46 ± 35 |
PK: Cmax of Warfarin
| ng/mL | Period 1: 10 mg Warfarin | Period 2: 10 mg Warfarin |
|---|---|---|
| PK: Cmax of Warfarin | 543 ± 18 | 506 ± 23 |
PK: Cmax of Dextromethorphan
| ng/mL | Period 1: 30 mg Dextromethorphan | Period 2: 30 mg Dextromethorphan |
|---|---|---|
| PK: Cmax of Dextromethorphan | 1.60 ± 154 | 1.47 ± 118 |
PK: Cmax of Omeprazole
| ng/mL | Period 1: 20 mg Omeprazole | Period 2: 20 mg Omeprazole |
|---|---|---|
| PK: Cmax of Omeprazole | 369 ± 137 | 437 ± 81 |
PK: Cmax of Caffeine
| ng/mL | Period 1: 100 mg Caffeine | Period 2: 100 mg Caffeine |
|---|---|---|
| PK: Cmax of Caffeine | 2400 ± 19 | 2340 ± 26 |
PK: Area Under the Concentration Curve (AUC) Time Zero to Infinity (AUC \[0-∞\]) of Midazolam
| Nanograms hour per millilitre (ng*h/mL) | Period 1: 1 mg Midazolam | Period 2: 1 mg Midazolam |
|---|---|---|
| PK: Area Under the Concentration Curve (AUC) Time Zero to Infinity (AUC [0-∞]) of Midazolam | 13.4 ± 43 | 15.6 ± 40 |
PK: AUC Time Zero to Infinity (AUC\[0-∞\]) of Warfarin
| ng*h/mL | Period 1: 10 mg Warfarin | Period 2: 10 mg Warfarin |
|---|---|---|
| PK: AUC Time Zero to Infinity (AUC[0-∞]) of Warfarin | 14800 ± 34 | 13800 ± 31 |
PK: AUC Time Zero to Infinity (AUC\[0-∞\]) of Dextromethorphan
| ng*h/mL | Period 1: 30 mg Dextromethorphan | Period 2: 30 mg Dextromethorphan |
|---|---|---|
| PK: AUC Time Zero to Infinity (AUC[0-∞]) of Dextromethorphan | 14.6 ± 160 | 13.0 ± 132 |
PK: AUC Time Zero to Infinity (AUC\[0-∞\]) of Omeprazole
| ng*h/mL | Period 1: 20 mg Omeprazole | Period 2: 20 mg Omeprazole |
|---|---|---|
| PK: AUC Time Zero to Infinity (AUC[0-∞]) of Omeprazole | 1280 ± 142 | 1530 ± 103 |
PK: AUC Time Zero to Infinity (AUC\[0-∞\]) of Caffeine
| ng*h/mL | Period 1: 100 mg Caffeine | Period 2: 100 mg Caffeine |
|---|---|---|
| PK: AUC Time Zero to Infinity (AUC[0-∞]) of Caffeine | 19700 ± 46 | 20800 ± 48 |
Collected over Baseline Up To 144 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Drug Cocktail | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) |
| Period 2: Mirikizumab | 0/29 (0%) | 0/29 (0%) | 3/29 (10.3%) |
| Period 2: Drug Cocktail | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) |
| Event | Period 1: Drug Cocktail | Period 2: Mirikizumab | Period 2: Drug Cocktail |
|---|---|---|---|
| Hand fractureInjury, poisoning and procedural complications | 0/29 | 2/29 | 0/29 |
| Limb injuryInjury, poisoning and procedural complications | 0/29 | 2/29 | 0/29 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 52.1 (31 to 79) |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 5 |
| Male | 24 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 11 |
| Not Hispanic or Latino | 18 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 24 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Participants |
|---|---|
| United States | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Oct 2019, 12 months.
Results were first posted in Jan 2024, 4 years 3 months after primary completion.
Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 12 months is above that.
Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab